Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

The Lancet Infectious Diseases(2019)

引用 137|浏览61
暂无评分
摘要
GlaxoSmithKline Biologicals SA.
更多
查看译文
关键词
recombinant zoster vaccine,haematological malignancies,post-hoc
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要